Tetsuya Ishii

Dr. Tetsuya Ishii


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Trends in Plant Science
Verified
Journal Article
Closed access
MAMotoko Araki
Motoko Araki
TITetsuya Ishii
Tetsuya Ishii

2 April 2016 in Plant Cell Reports
Verified
Journal Article
Closed access
PDF file
TITetsuya Ishii
Tetsuya Ishii
MAMotoko Araki
Motoko Araki

14 December 2016 in GM Crops & Food
Verified
Journal Article
Open access
TITetsuya Ishii
Tetsuya Ishii
MAMotoko Araki
Motoko Araki
The global agricultural landscape regarding the commercial cultivation of genetically modified (GM) crops is mosaic. Meanwhile, a new plant breeding technique, genome editing is expected to make genetic engineering-mediated crop breeding more socially acceptable because it can be used to develop crop varieties without introducing transgenes, which have hampered the regulatory review and public acceptance of GM crops. The present study revealed that product- and process-based concepts have been implemented to regulate GM crops in 30 countries. Moreover, this study analyzed the regulatory responses to genome-edited crops in the USA, Argentina, Sweden and New Zealand. The findings suggested that countries will likely be divided in their policies on genome-edited crops: Some will deregulate transgene-free crops, while others will regulate all types of crops that have been modified by genome editing. These implications are discussed from the viewpoint of public acceptance.

1 January 2014 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
PDF file
MAMotoko Araki
Motoko Araki
TITetsuya Ishii
Tetsuya Ishii
Genome editing technology, including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)/Cas, has enabled far more efficient genetic engineering even in non-human primates. This biotechnology is more likely to develop into medicine for preventing a genetic disease if corrective genome editing is integrated into assisted reproductive technology, represented by in vitro fertilization. Although rapid advances in genome editing are expected to make germline gene correction feasible in a clinical setting, there are many issues that still need to be addressed before this could occur. We herein examine current status of genome editing in mammalian embryonic stem cells and zygotes and discuss potential issues in the international regulatory landscape regarding human germline gene modification. Moreover, we address some ethical and social issues that would be raised when each country considers whether genome editing-mediated germline gene correction for preventive medicine should be permitted.

1 January 2014 in World Journal of Stem Cells
Verified
Journal Article
Open access
TITetsuya Ishii
Tetsuya Ishii
KEKoji Eto
Koji Eto
Fetal stem cell transplantation: Past, present, and future

27 November 2015 in Briefings in Functional Genomics
Verified
Journal Article
Open access
PDF file
TITetsuya Ishii
Tetsuya Ishii
Genome editing allows for the versatile genetic modification of somatic cells, germ cells and embryos. In particular, CRISPR/Cas9 is worldwide used in biomedical research. Although the first report on Cas9-mediated gene modification in human embryos focused on the prevention of a genetic disease in offspring, it raised profound ethical and social concerns over the safety of subsequent generations and the potential misuse of genome editing for human enhancement. The present article considers germ line genome editing approaches from various clinical and ethical viewpoints and explores its objectives. The risks and benefits of the following three likely objectives are assessed: the prevention of monogenic diseases, personalized assisted reproductive technology (ART) and genetic enhancement. Although genetic enhancement should be avoided, the international regulatory landscape suggests the inevitability of this misuse at ART centers. Under these circumstances, possible regulatory responses and the potential roles of public dialogue are discussed.